Results 101 to 110 of about 50,964 (281)

Tributyltin Protumorigenic Effects Targeting Prostate Cancer Cell Metabolism, Proliferation, Migration, and Invasion

Environmental Toxicology, EarlyView.
ABSTRACT Prostate cancer (PCa) is an endocrine‐related cancer highly dependent on androgenic signaling. Beyond hormone dependence, extrinsic factors play a significant role in the risk of developing PCa, which raises concern about the influence of environmental compounds such as endocrine‐disrupting chemicals (EDCs). Tributyltin (TBT) is an EDC used in
Mariana Feijó, Luís P. Brás, Catarina M. D. Serra, Lara R. S. Fonseca, Sara Correia, Bruno J. Pereira, Ana P. Duarte, Henrique J. Cardoso, Cátia V. Vaz, Sílvia Socorro   +9 more
wiley   +1 more source

Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.

PURPOSE: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping based on gene expression has been less studied, especially using large cohorts.
Quigley, DA, Sjöström, M, Feng, E, Lundberg, A, Rydzewski, NR, Helzer, KT, Aggarwal, R, Zhang, M, Zhao, SG, Bootsma, M, Small, EJ, Lang, JM   +11 more
core   +1 more source

RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.

, 2019
PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal but clinically heterogeneous disease, with patients having variable benefit from endocrine and cytotoxic treatments.
Crespo, M, Makay, A, Rescigno, P, Mateo, J, Sharp, A, Romanel, A, McNair, C, Riisnaes, R, Carreira, S, Nava Rodrigues, D, Knudsen, K, Demichelis, F, de Bono, JS, Casiraghi, N, Miranda, S, Figueiredo, I, Sumanasuriya, S, Schiewer, M, Boysen, G, Gasperini, P   +19 more
core   +1 more source

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer

Nature Communications, 2020
MUC1-C is overexpressed in castration-resistant prostate cancer and neuroendocrine prostate cancer. Here, the authors show that MUC1-C drives lineage plasticity through MYC and BRN2, inducing neuroendocrine features and stemness in prostate cancer.
Yota Yasumizu, Hasan Rajabi, Caining Jin, Tsuyoshi Hata, Sean Pitroda, Mark D. Long, Masayuki Hagiwara, Wei Li, Qiang Hu, Song Liu, Nami Yamashita, Atsushi Fushimi, Ling Kui, Mehmet Samur, Masaaki Yamamoto, Yan Zhang, Ning Zhang, Deli Hong, Takahiro Maeda, Takeo Kosaka, Kwok K. Wong, Mototsugu Oya, Donald Kufe   +22 more
doaj   +1 more source

Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers

UroPrecision, EarlyView.
Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley   +1 more source

RGS2 is prognostic for development of castration resistance and cancer‐specific survival in castration‐resistant prostate cancer

, 2020
Background Regulator of G-protein signaling 2 (RGS2) is a multifaceted protein with a prognostic value in hormone-naive prostate cancer (PC). It has previously been associated with the development of castration resistance.
Damber, Jan-Erik,, Larsson, Karin,, Welén, Karin,, Linder, Anna,, Anna Linder, Jan‐Erik Damber, Karin Larsson, Karin Welén   +7 more
core   +1 more source

Recent progress on the development of hydrogel‐based microneedles for transdermal drug delivery

VIEW, EarlyView.
This study provides a comprehensive and up‐to‐date analysis of recent progress in HMN technology, covering fundamental transdermal delivery mechanisms and design principles, biomaterials used in HMN fabrication, drug loading and release strategies, and emerging therapeutic applications.
Mohammad Muhtasim Ittisaf, Salman Farsi Taharat, Md. Sadek Miah, Hasan Tasnim Salehin, M. Azam Ali, Shoeb Ahmed   +5 more
wiley   +1 more source

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses

Nature Communications, 2018
The functional significance of the observed heterogeneity of androgen receptor (AR) expression in prostate cancer is unknown. Here the authors show AR expression heterogeneity is associated with distinct castration/enzalutamide responses and identify BCL-
Qiuhui Li, Qu Deng, Hsueh-Ping Chao, Xin Liu, Yue Lu, Kevin Lin, Bigang Liu, Gregory W. Tang, Dingxiao Zhang, Amanda Tracz, Collene Jeter, Kiera Rycaj, Tammy Calhoun-Davis, Jiaoti Huang, Mark A. Rubin, Himisha Beltran, Jianjun Shen, Gurkamal Chatta, Igor Puzanov, James L. Mohler, Jianmin Wang, Ruizhe Zhao, Jason Kirk, Xin Chen, Dean G. Tang   +24 more
doaj   +1 more source

Management of Metastatic Castration-resistant Prostate Cancer [PDF]

European Oncology & Haematology, 2011
The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forwards in the last two years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel and abiraterone acetate) and a significant delay in skeletal-related events observed with denosumab. The pipeline
openaire   +2 more sources

Utility of SUVmax on Primary Staging 68Ga‐PSMA PET in Determining Metastatic Status of Prostate Cancer

Journal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT Introduction 68Ga prostate‐specific membrane antigen (PSMA) has been shown to have prognostic value in detecting PSMA expressing metastasis from prostate cancer, but inevitably, there are cases in which suspected metastases demonstrate equivocal uptake.
Geoffrey Liu, Shane Lee, Kabir Ahmad
wiley   +1 more source